BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
BMRN$57.18+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2023 and 2022
(In thousands of U.S. Dollars, except share and per share amounts)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $755,127 | $724,531 |
| Short-term investments | 318,683 | 567,006 |
| Accounts receivable, net | 633,704 | 461,316 |
| Inventory | 1,107,183 | 894,083 |
| Other current assets | 141,391 | 104,521 |
| Total current assets | 2,956,088 | 2,751,457 |
| Noncurrent assets: | ||
| Long-term investments | 611,135 | 333,835 |
| Property, plant and equipment, net | 1,066,133 | 1,073,366 |
| Intangible assets, net | 294,701 | 338,569 |
| Goodwill | 196,199 | 196,199 |
| Deferred tax assets | 1,545,809 | 1,505,412 |
| Other assets | 171,538 | 176,236 |
| Total assets | $6,841,603 | $6,375,074 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $683,147 | $572,959 |
| Short-term convertible debt, net | 493,877 | — |
| Short-term contingent consideration | — | 15,925 |
| Total current liabilities | 1,177,024 | 588,884 |
| Noncurrent liabilities: | ||
| Long-term convertible debt, net | 593,095 | 1,083,019 |
| Other long-term liabilities | 119,935 | 100,015 |
| Total liabilities | 1,890,054 | 1,771,918 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value: 500,000,000 shares authorized; 188,598,154 and 186,250,719 shares issued and outstanding, respectively | 189 | 186 |
| Additional paid-in capital | 5,611,562 | 5,404,895 |
| Company common stock held by the Nonqualified Deferred Compensation Plan | (9,860) | (8,859) |
| Accumulated other comprehensive loss | (28,788) | (3,867) |
| Accumulated deficit | (621,554) | (789,199) |
| Total stockholders’ equity | 4,951,549 | 4,603,156 |
| Total liabilities and stockholders’ equity | $6,841,603 | $6,375,074 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.